Due Diligence in Acquisition of Non-Prescription Drug and Personal Care Manufacturer

Epstein Becker Green (EBG) performed regulatory due diligence for a private equity firm and its portfolio company in the acquisition of a large-contract non-prescription drug and personal care manufacturer with operations in the United States and Canada. EBG assessed the target company’s compliance with FDA and other international consumer and health care product regulations and provided strategies to mitigate future regulatory enforcement risk.